PMID- 32166504
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20221202
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Mar 12
TI  - A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter 
      Inhibitors for Type 2 Diabetes.
PG  - 12
LID - 10.1007/s11892-020-1292-5 [doi]
AB  - PURPOSE OF REVIEW: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the 
      most recently approved class of drugs (since 2012) for type 2 diabetes mellitus 
      (T2DM), but their economic merits have yet been fully confirmed. The objective of 
      this review was to evaluate the most updated evidence that examined the 
      cost-effectiveness of SGLT2i for T2DM. RECENT FINDINGS: We systematically 
      searched Medline (PubMed), EMBASE, and Web of Science for eligible articles from 
      January 1, 2011, to October 31, 2019, using combinations of search words. A 
      supplementary search using reference lists of eligible articles and other review 
      articles was also performed. A multistage screening process was carried out with 
      duplicates removal, abstract screening, and full-text reading to confirm 
      eligibility. Two reviewers independently screened the eligible articles and 
      assessed reporting quality using the Consolidated Health Economic Evaluation 
      Reporting Standards (CHEERS) checklist. A total of 24 studies were included in 
      the final review. All studies showed good quality according to the CHEERS 
      checklist (scored 21-24). Seven studies compared SGLT2i vs. dipeptidyl 
      peptidase-4 inhibitors (DPP-4i), 3 studies compared SGLT2i vs. sulfonylureas 
      (SU), 3 compared SGLT2i vs. glucagon-like peptide-1 receptor agonist (GLP-1 RA), 
      2 compared SGLT2i vs. SGLT2i, 3 compared SGLT2i vs. other antidiabetic therapies 
      including thiazolidinediones (TZD), alpha-glucosidase inhibitors (AGI) or 
      insulin, and 5 compared SGLT2i vs. standard care/metformin. Most studies 
      concluded SGLT2i was cost-effective relative to its comparator except GLP-1 RA, 
      where two studies suggested GLP-1 RA was the favorable treatment option relative 
      to SGLT2i. The literature demonstrated that SGLT2i may be cost-effective compared 
      to many antidiabetic therapies including DPP-4i, SU, TZD, AGI, insulin, and 
      standard care .
FAU - Yoshida, Yilin
AU  - Yoshida Y
AD  - Section of Endocrinology, Department of Medicine, School of Medicine, Tulane 
      University, New Orleans, LA, USA.
FAU - Cheng, Xi
AU  - Cheng X
AD  - Department of Health Services and Policy Management, School of Public Health, 
      University of South Carolina, Columbia, SC, USA.
FAU - Shao, Hui
AU  - Shao H
AD  - Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University 
      of Florida, Gainesville, FL, USA.
FAU - Fonseca, Vivian A
AU  - Fonseca VA
AD  - Section of Endocrinology, Department of Medicine, School of Medicine, Tulane 
      University, New Orleans, LA, USA.
FAU - Shi, Lizheng
AU  - Shi L
AD  - Department of Health Policy and Management, School of Public Health and Tropical 
      Medicine, Tulane University, 1440 Canal St. Tidewater building, suite 1900, New 
      Orleans, LA, 70112, USA. lshi1@tulane.edu.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200312
PL  - United States
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy/economics
MH  - Humans
MH  - Sodium-Glucose Transporter 2 Inhibitors/economics/*therapeutic use
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
OT  - Type 2 diabetes
EDAT- 2020/03/14 06:00
MHDA- 2020/09/15 06:00
CRDT- 2020/03/14 06:00
PHST- 2020/03/14 06:00 [entrez]
PHST- 2020/03/14 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
AID - 10.1007/s11892-020-1292-5 [pii]
AID - 10.1007/s11892-020-1292-5 [doi]
PST - epublish
SO  - Curr Diab Rep. 2020 Mar 12;20(4):12. doi: 10.1007/s11892-020-1292-5.